NURS reports record Q2 revenue and profit, reaffirms guidance
Record Q2 revenue and profit were driven by broad-based growth, especially in direct-to-consumer and pharmacy segments. Full-year guidance was reaffirmed on expected regulatory tailwinds and strong demand.
Record Q2 revenue and profit driven by broad-based growth, especially in direct-to-consumer and pharmacy segments.
Full-year guidance reaffirmed, with regulatory changes and strong demand expected to accelerate H2 results.Based on Hydreight Technologies Inc [NURS] Q2 2026 Audio Transcript — Sep.
1…